← The Protocols
The Cellvéra injector — CJC-1295 (with DAC) protocol

Growth Hormone · Research compound

CJC-1295 (with DAC)

Long‑acting GHRH analogue · Growth · Recovery

The long-acting GHRH analogue — a half-life of days rather than minutes.

Form
10 mg — pre-reconstituted in the Cellvéra injector
Oversight
Licensed clinician, included
Price
From R5 180 / protocol
Begin your intake

Opens a private email to our concierge · nothing is charged

Checkout begins your confidential medical intake. CJC-1295 (with DAC) is dispensed only if a licensed clinician prescribes it after reviewing your intake — nothing is charged until your provider approves.

Pathway

The same GHRH analogue as Modified GRF (1-29) with a Drug Affinity Complex attached — a chemical handle that binds it to albumin, a protein circulating in the blood.

Mechanism

Binding to albumin shields it from breakdown and extends its half-life dramatically — from about half an hour to roughly six to eight days. Instead of discrete pulses, it produces a sustained elevation of growth hormone, sometimes described as a "GH bleed."

Studied for

  • Sustained elevation of growth hormone and IGF-1 from far fewer injections
  • Recovery, body composition and anti-ageing goals

Areas of research interest — not promised outcomes.

Where the evidence stands

Developed by ConjuChem and taken into early human trials, which were discontinued. Continuous rather than pulsed growth-hormone exposure is less physiological than the body’s natural pattern, and the long-term consequences of that have not been established in people.

Typical protocol

Dosing is individualised and set by your supervising clinician at intake. Published human dosing for this compound is not established; conservative titration and monitoring are part of every protocol.

Contraindications & cautions

Not an approved medicine. The very long half-life means it cannot be stopped quickly if something goes wrong. Sustained IGF-1 elevation — caution regarding malignancy risk. Prohibited in competitive sport (WADA). Pregnancy or breastfeeding.

Prescribed only after evaluation by your supervising provider, based on your history and bloodwork.

Important safety information
CJC-1295 (with DAC) is dispensed as a compounded preparation under valid prescription only. Compounded medications are not FDA-evaluated for safety or efficacy. Report adverse events to your supervising clinician immediately. Keep refrigerated; keep out of reach of children.